Glassy Mountain Advisors Inc. Makes New Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Glassy Mountain Advisors Inc. acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 151 shares of the medical research company’s stock, valued at approximately $83,000.

Several other institutional investors have also recently made changes to their positions in the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in Thermo Fisher Scientific by 168.1% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,014,472 shares of the medical research company’s stock valued at $1,094,244,000 after buying an additional 1,262,989 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Thermo Fisher Scientific by 394.8% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,110,504 shares of the medical research company’s stock worth $563,237,000 after buying an additional 886,075 shares during the period. Ontario Teachers Pension Plan Board purchased a new position in Thermo Fisher Scientific during the third quarter valued at $433,169,000. Canada Pension Plan Investment Board purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $209,946,000. Finally, Vanguard Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 1.3% in the third quarter. Vanguard Group Inc. now owns 32,166,910 shares of the medical research company’s stock worth $16,314,735,000 after acquiring an additional 406,844 shares during the last quarter. Hedge funds and other institutional investors own 85.92% of the company’s stock.

Insider Activity

In related news, Director Jim P. Manzi sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $584.56, for a total value of $584,560.00. Following the transaction, the director now owns 14,807 shares in the company, valued at $8,655,579.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Jim P. Manzi sold 1,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $584.56, for a total transaction of $584,560.00. Following the transaction, the director now owns 14,807 shares in the company, valued at approximately $8,655,579.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 1,600 shares of the stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $571.96, for a total value of $915,136.00. Following the completion of the sale, the chief executive officer now owns 128,705 shares of the company’s stock, valued at $73,614,111.80. The disclosure for this sale can be found here. Insiders have sold 30,100 shares of company stock valued at $16,966,971 in the last three months. Corporate insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.8 %

Thermo Fisher Scientific stock traded down $9.75 during trading on Friday, hitting $547.34. The company’s stock had a trading volume of 1,947,936 shares, compared to its average volume of 1,498,879. The stock’s fifty day moving average is $565.91 and its 200 day moving average is $545.06. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.48. Thermo Fisher Scientific Inc. has a 1-year low of $475.77 and a 1-year high of $618.35. The stock has a market capitalization of $210.96 billion, a price-to-earnings ratio of 31.05, a P/E/G ratio of 1.88 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last released its earnings results on Wednesday, February 1st. The medical research company reported $5.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.19 by $0.21. The business had revenue of $11.45 billion for the quarter, compared to analysts’ expectations of $10.41 billion. Thermo Fisher Scientific had a net margin of 15.47% and a return on equity of 21.42%. The company’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the company earned $6.54 earnings per share. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.72 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 14th. Shareholders of record on Wednesday, March 15th will be paid a dividend of $0.35 per share. The ex-dividend date of this dividend is Tuesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.30. This represents a $1.40 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is currently 7.94%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Cowen increased their price target on Thermo Fisher Scientific from $690.00 to $711.00 and gave the company an “outperform” rating in a report on Thursday, February 2nd. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $613.00 to $670.00 and gave the company an “overweight” rating in a report on Thursday, February 2nd. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $710.00 to $693.00 in a research note on Thursday, February 2nd. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Finally, SVB Leerink raised their target price on Thermo Fisher Scientific from $620.00 to $630.00 and gave the stock an “outperform” rating in a research report on Thursday, February 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $647.00.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.